TORONTO, Nov. 28, 2019 /CNW/ - Trichome Financial Corp.
(formerly 22 Capital Corp.) (the "Company" or "Trichome
Financial") (TSXV: TFC) today announced its financial results
for the three and nine-month periods ended September 30, 2019.
The complete Financial Statements and Management's Discussion
and Analysis for the three- and nine-month periods ended
September 30, 2019, along with
additional information about the Company and all of its public
filings are available at www.sedar.com.
Third quarter highlights
Highlights during the quarter ended September 30, 2019:
- Entered into a $5.5 million
senior secured term loan to MYM Nutraceuticals Inc. (CSE:MYM), of
which $3 million was funded on
closing, and a $2.35 million senior
secured term loan to Good Buds Company International Inc.;
- Received full repayment of loans to C.G.S. Foods Inc. (an
Ontario cannabis retailer doing
business as 'Ganjika House') in the amount of $1.25 million and early repayment of the
Company's loan to Blissco Holdings Ltd. in the amount of
$1.4 million
- Total par value of investments increased to $8.9 million with a further $2.5 million in commitments, compared to
$0.5 million as of December 31, 2018; and
- Appointed Karl Grywacheski as
Chief Financial Officer and Dan
Cohen as Vice President, General Counsel of Trichome
Financial.
Highlights subsequent to the quarter ended September 30, 2019:
- Completed a reverse takeover with 22 Capital Corp. on
October 4, 2019, and listed on the
TSXV under ticker symbol "TFC" on October
10, 2019;
- Closed a private placement on October 4,
2019, raising gross proceeds of approximately $16.5 million resulting in pro forma cash of
$21.1 million and pro forma working
capital of $24.4 million;
- Increased the loan agreement to James E. Wagner Cultivation
Corporation ("JWC") (TSXV:JWCA) to $7.5
million from $3.5
million;
- Entered into the Company's first receivables financing facility
with JWC for up to $5.0 million;
and
- Received conditional approval to list its common shares on the
Canadian Securities Exchange, with successful listing to allow the
Company to expand its addressable market for credit solutions to
include the cannabis sector in the United
States.
"The operational and funding challenges the cannabis sector has
experienced in the last six months have been a significant tailwind
to Trichome Financial. Our deal pipeline continues to increase, and
the quality of actionable opportunities has high-graded materially.
Consequently, we believe the risk-return profile of our investment
opportunities remains very attractive," said Michael Ruscetta, Chief Executive Officer. "The
need for credit in the cannabis sector is expected to continue
increasing at a rapid pace and Trichome Financial remains in an
excellent position to capitalize on these opportunities."
Outlook
The current environment in the cannabis sector is highly
favourable for Trichome Financial. Our business model is unique in
that it benefits from both the structural, long-term growth of the
global cannabis industry as well periods of market volatility when
investor confidence wanes. Since the middle of 2019, a series of
events have contributed to creating a negative feedback loop for
investor confidence in the cannabis sector. A detailed discussion
of these events, as well as key learnings by management of Trichome
Financial over the last 18 months was published by the Company in a
press release on October 7, 2019.
Since then, operational and financial performance in the cannabis
sector have only deteriorated. This has led to a highly favourable
environment for Trichome Financial characterized by an increase in
the number of companies in need of Trichome's solutions, an
increase in overall borrower quality as a result of being able to
select from an even larger pool of opportunities and improving
risk-adjusted return profiles through increasing contractual
returns, higher warrant and equity coverage and more favourable
structural enhancements.
Trichome has raised gross proceeds of approximately $31.8 million and is in the process of
constructing a portfolio of diligently underwritten and structured
income generating credit investments. To date, Trichome has closed
seven credit transactions to six unique counterparties, with three
of those loans having been fully repaid. As at September 30, 2019 the par value of loans
outstanding was $8.9 million, with a
further $2.5 million committed.
Subsequent to quarter end, the par value of loans outstanding
increased to $11.7 million with a
further $3.7 million committed. The
weighted average effective interest rate of the portfolio is
approximately 14%, excluding warrants and equity consideration, and
the annualized interest revenue from the portfolio is approximately
$1.8 million. Interest revenue is
expected to grow commensurately with further deployment of the
Company's cash into income-generating credit investments. This
amount could be partially offset by any prepayments or early
terminations. Total cash-based operating expenses are estimated to
be approximately $1.9 million on an
annualized basis, excluding one-time listing and fund set-up costs,
which could increase by approximately $0.6
million if annual bonus payments are merited. Management
expects modest increases in the expense base to continue the
buildout of Trichome's infrastructure. No capital expenditures are
planned. Management believes that the proceeds from the disposition
of warrants and shares, fee income from the launch of Trichome
Financial Cannabis Private Credit Fund ("Trichome Private Credit"),
the accretive effect of adding portfolio leverage, and the
potential to launch complimentary business lines has the potential
to materially increase overall profitability.
Financial results for the three months ended September 30, 2019
For the quarter ended September 30,
2019, interest revenue increased to $412,304 from $9,437 compared to the quarter ended September 30, 2018. This is the result of the par
value of total investments increasing over the course of the year
to $8.9 million at quarter end, from
$0.5 million as of December 31, 2018.
Trichome Financial realized an adjusted loss of $343,276 as compared to $514,847 in the prior year. Offsetting the
increase in interest revenue were increases to operating expenses
related to hiring new employees, leasing office space, insurance
and expenses incurred to perform due diligence on new loans, such
as legal, professional, and travel costs. Adjusted loss is
calculated by excluding certain non-cash and non-recurring items
from net loss as calculated under IFRS.
Cash and restricted cash totaled $15.9
million as of September 30,
2019, compared to $13.8
million on December 31, 2018.
Subsequent to its private placement on October 4, 2019, the Company had pro forma cash
of $21.1 million and pro forma
working capital of $24.4 million.
Summary of
operations
|
Three months ended
September
30, 2019
|
Three months
ended
September 30, 2018
|
Nine months
ended
September 30, 2019
|
Nine months ended
September 30, 2018
|
|
|
|
|
|
Interest
revenue
|
$
|
412,304
|
$
|
9,437
|
$
|
693,368
|
$
|
12,930
|
Operating
loss
|
(548,879)
|
(888,297)
|
(1,794,874)
|
(1,099,807)
|
Total net and
comprehensive loss
|
(1,117,908)
|
(923,784)
|
(3,147,227)
|
(1,135,294)
|
Adjusted
loss1
|
(343,276)
|
(514,847)
|
(888,795)
|
(679,122)
|
|
|
|
|
|
|
|
As at September
30, 2019
|
As at September 30,
2018
|
|
|
|
|
|
Cash and restricted
cash2
|
|
$15,928,799
|
$13,810,095
|
|
|
|
|
|
Loan
book:
|
Term /
Interest rate
|
Loan
amount
|
Term /
Interest rate
|
Loan
amount
|
James E. Wagner
Cultivation Corporation (JWC)
|
24 months /
9.25%
|
$3,500,000
|
-
|
-
|
Good Buds Company
International Inc. (Good Buds)
|
13 months /
11.5%
|
$2,350,000
|
-
|
-
|
MYM Nutraceuticals
Inc. (MYM)
|
12 months /
12.0%
|
$3,000,000
|
-
|
-
|
180 Smoke Inc. (180
Smoke)
|
-
|
-
|
12 months /
10.0%
|
$425,000
|
Total loan
book
|
$8,850,000
|
|
$425,000
|
Committed
capital:
|
MYM:
|
$2,500,000
|
-
|
-
|
|
JWC
(factoring):
|
$5,000,000
|
-
|
-
|
|
-
|
-
|
180 Smoke:
|
$2,075,000
|
Other
highlights:
|
|
|
|
|
Fair value of
warrants
|
|
$574,216
|
$17,314
|
|
|
Loan
amount
|
|
Loan
amount
|
Loans fully repaid
during year:
|
180 Smoke
|
$425,000
|
-
|
-
|
|
Blissco Holdings
Ltd.
|
$1,500,000
|
-
|
-
|
|
C.G.S. Food Inc.
d/b/a Ganjika House
|
$1,250,000
|
-
|
-
|
(1) Refer to
Adjusted losssection within Management's Discussion and
Analysis
|
(2) Restricted cash
was converted to free cash on October 4, 2019. Additional $6
million cash raised in October 2019
|
About Trichome Financial Corp.
Trichome Financial is a specialty finance company focused on
providing flexible and creative credit solutions to the global
legal cannabis market. Trichome was created to address the lack of
credit availability in the large, growing and increasingly complex
cannabis market. Founded by industry leaders Origin House and Stoic
Advisory, Trichome Financial's experienced management team has a
unique edge to capitalize on proprietary deal flow and industry
insight while developing a first mover advantage as a global
cannabis focused specialty finance company. Trichome Financial
provides customized financing solutions across the industry value
chain to support growth, capital expenditures, mergers,
acquisitions, working capital and other needs. Leveraging the
combined resources and knowledge of its founders, it is able to
offer significant value-added financial, product, market and
operational support to its partner companies. Trichome Financial's
current assets are all based in Canada and it has no operations or assets in
the United States.
For further information about Trichome Financial please visit us
at www.trichomefinancial.com or @trichomefinance on Twitter and
refer to the joint information circular of Trichome Financial and
22 Capital dated May 29, 2019 which
is available on the Company's SEDAR profile at www.sedar.com.
READER ADVISORY
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things: the Company's effective cash interest
yield, effective interest rate, interest revenue, cash-based
operation expenses, the development of the global cannabis industry
and trends in the cannabis capital markets, the future market
opportunity for Trichome Financial and factors that may improve
future profitability. Forward-looking statements are necessarily
based upon a number of estimates and assumptions that, while
considered reasonable, are subject to known and unknown risks,
uncertainties, and other factors which may cause the actual results
and future events to differ materially from those expressed or
implied by such forward-looking statements. Such factors include,
but are not limited to: general business, economic, competitive,
political and social uncertainties; and the delay or failure to
receive board, shareholder or regulatory approvals. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, Trichome Financial assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities described
herein. The securities have not been and will not be registered
under the United States Securities Act of 1933, as amended (the
"U.S. Securities Act"), or any state securities laws and may
not be offered or sold within the United
States or to United States Persons unless registered under
the U.S. Securities Act and applicable state securities laws or an
exemption from such registration is available.
Non-IFRS Financial Measures
The Company reports non-IFRS financial measures, including
adjusted loss and adjusted loss per share, as key measures used by
management to evaluate performance of the business, to compensate
employees and to facilitate a comparison of quarterly and annual
results of ongoing operations. While used to assist in
evaluating the operating performance of the Company, readers are
cautioned that adjusted loss as reported by the Company may not be
comparable in all instances to adjusted loss as reported by other
companies. For a detailed explanation of how the Company's
non-IFRS measures are calculated, please refer to the Company's
MD&A filing for the three and nine months ended September 30, 2019, which can be accessed via the
SEDAR Web site (www.sedar.com).
SOURCE Trichome Financial Corp.